A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies
Latest Information Update: 04 Apr 2025
At a glance
- Drugs AZD 3470 (Primary)
- Indications Haematological malignancies; Hodgkin's disease
- Focus Adverse reactions; First in man
- Acronyms PRIMAVERA
- Sponsors AstraZeneca
Most Recent Events
- 10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
- 14 May 2024 Planned End Date changed from 16 Apr 2026 to 8 May 2026.
- 14 May 2024 Planned primary completion date changed from 16 Apr 2026 to 8 May 2026.